Alkermes plc Q3 2026 Earnings Call Summary

Alkermes reported Q3 2026 earnings, highlighting 31% year-over-year growth in proprietary product sales, with 2026 sales expected to reach $1.6 billion. The company is expanding its orexin portfolio into ADHD and MDD, with six major clinical readouts anticipated in 2027. LUMRYZ's market access expanded to 80% of covered lives, and management expects net sales acceleration in 2027. The company maintains a strong financial position with $787 million in cash and investments.

Original reporting
Published Nov 3, 2026, 5:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 6:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alkermes plc Q3 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

$ALKSBullishMed
01

Why it matters

The most tradable elements are the quantified commercial assumptions (2026 proprietary sales growth, LYBALVI access and 2027 gross-to-net range) and the stated 2027 clinical readout slate plus contingent launch timing for LUMRYZ in IH.

02

Market read

Traders can reassess Alkermes’ 2027 catalyst probability-weighting and commercial ramp expectations based on the call’s quantified assumptions and stated clinical readout schedule.

03

What to watch

Gross-to-net settling and COGS normalization are model assumptions; near-term margin and inventory dynamics (LUMRYZ inventory drawdown/build) could create volatility around quarterly reporting.

Relevance 7/10Novelty 6/10Timing: into the next trading session after the earnings call, with 2027 catalyst calendar in focus

Background

This is a summary of Alkermes’ Q3 2026 earnings call, emphasizing strategy, commercial performance, and a 2027 orexin-focused clinical catalyst plan.

Company-level read

Ticker impact

$ALKSBullishMedium confidence
Context

Alkermes’ Q3 call outlines 2027 orexin pipeline readouts, LUMRYZ/LYBALVI commercial targets, and updated COGS normalization assumptions tied to the Avadel acquisition.

Expected impact

Likely upward bias as investors price in a data-rich 2027 calendar and clearer commercialization trajectory for LUMRYZ and LYBALVI.

Evidence & confidence

The article provides forward-looking, decision-relevant specifics (2027 readouts count, gross-to-net range, launch contingency timing, and COGS normalization) that can re-rate expectations even without a new earnings print.

Market effects

Reinforces competitive framing in orexin agonists versus antagonists and oxybate, potentially affecting sentiment across CNS/psychiatry drug developers.

Limited direct regional spillover; primarily US biotech/CNS investor positioning.

Moderate, as orexin competition and clinical timelines are globally relevant for CNS investors, but the disclosure is company-specific.

Counterpoint

The call’s optimism depends on multiple clinical readouts and regulatory steps; investors may discount the 2027 calendar if trial outcomes or sNDA timing slip.

Key entities

  • Alkermes plc

    Subject of the earnings call summary, discussing orexin portfolio expansion, 2027 clinical catalysts, and 2027 financial modeling assumptions.

  • LUMRYZ

    Orexin-related therapy discussed for potential IH launch timing contingent on sNDA after Phase 3 REVITALIZE data.

  • LYBALVI

    Antipsychotic franchise discussed with expanded market access and a 2027 gross-to-net adjustment target.

  • VIVITROL

    Alcohol dependence product referenced for gross-to-net and inventory favorability impacts in Q3.

  • ARISTADA

    Alcohol dependence product referenced for gross-to-net and inventory favorability impacts in Q3.

Related articles

$TAKHighAI 8/10

Awake to the possibilities: a ‘first in class’ narcolepsy drug could be transformational

Takeda's narcolepsy drug Orzeyful (oveporexton), approved by the FDA in 2026, targets the underlying cause of type 1 narcolepsy by activating orexin receptors. The drug, taken twice daily, shows immediate effects but has some side effects. Takeda seeks UK approval. Other companies like Eli Lilly, Alkermes, and Lundbeck are also developing orexin agonists for sleep disorders. (350 characters)

$ALKSMed

H.C. Wainwright raises Alkermes stock price target to $50 on pipeline progress

H.C. Wainwright raised its price target for Alkermes (ALKS) to $50 from $43, citing progress in its clinical pipeline and commercial revenue. The stock is up 63% year-to-date. The firm maintained a Neutral rating. Alkermes recently reported stronger-than-expected Q3 2026 results, with adjusted earnings of $0.09 per share and revenue of $480.1 million. Baird and Wells Fargo also raised their price targets.

$ALKSMed

Alkermes PLC (ALKS) Q3 2026 Earnings Call Highlights: Proprietary Sales Surge 31%

Alkermes PLC (ALKS) reported a 31% surge in proprietary sales for Q3 2026, but R&D and SG&A expenses rose due to the Avadel acquisition and expanded orexin development. LYBALVI's gross-to-net adjustments are expected to reach 45% in 2027, potentially pressuring net sales growth. The company faces competition from Takeda's oveporexton in the narcolepsy market. Alkermes expects to provide full 2027 financial guidance in February, leaving investors with uncertainty.

$ALKSHighAI 8/10

Alkermes (ALKS) Q3 2026 Earnings Call Transcript

Alkermes (ALKS) reported Q3 2026 net sales of $417.3M, up 31% YoY. Key products include VIVITROL ($127.6M), ARISTADA ($103.9M), LYBALVI ($95.9M), and LUMRYZ ($89.9M). Full-year guidance remains unchanged. The company expects continued growth in 2027 and beyond, driven by expanded payer access and new product launches.